

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, WITHIN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEELAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SWITZERLAND, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, DISTRIBUTION OR RELEASE WOULD BE CONTRAVENING TO ANY APPLICABLE RULES OR REQUIRE REGISTRATION OR OTHER ACTIONS. PLEASE REFER TO THE SECTION "IMPORTANT INFORMATION" BELOW.

Iconovo AB evaluates the conditions to carry out a directed new share issue of approximately SEK 50 million and brings forward publication of the year-end report for the financial year 2022

Iconovo AB ("Iconovo" or the "Company") has mandated Danske Bank A/S, Danmark, Sverige Filial ("Danske Bank") to evaluate the conditions to carry out a directed new share issue of approximately SEK 50 million (the "New Share Issue"). The subscription price and the total number of new shares in the New Share Issue will be determined through an accelerated bookbuilding procedure (the "Bookbuilding") targeting institutional investors. Several current shareholders, among others Eiffel Investment Group ("Eiffel"), have expressed strong support for the New Share Issue and intends to participate in the New Share Issue with significant amounts. Due to the New Share Issue, the Board of Directors has resolved to bring forward the publication of the Company's year-end report for the financial year 2022. The year-end report will be published directly after this press release.

Iconovo intends to use the proceeds from the New Share Issue for accelerating and value-creational development and initiatives connected to the Company's long-term strategy. During 2022, the Company has continued to invest in the value chain of its product platforms ICOpre, ICOone and ICOcap in order to attract more business and take advantage of strategic opportunities. The commercial potential in ICOres is evidenced through the ongoing collaboration with Amneal that is expected to result in a European regulatory filing in 2024. In January 2023, Iconovo announced that discussions with an international complex generics company is ongoing regarding a collaboration involving ICOpre. In addition to licensing its products to international partners, Iconovo is aiming to launch Iconovo Pharma, a subsidiary focusing on selling and distributing pharmaceuticals in the Nordic region.

Against this background, the Company intends to use the proceeds from the New Share Issue to enable the following growth and value-adding activities:

- **ICOpre (generic asthma/COPD)** – negotiate agreement and complete development and regulatory work for all five product formulations in ICOpre, ~30 percent
- **ICOcap (generic Ultibro)** – move the project forward including the first PK trial, seeking partnership for Europe with a launch opportunity in 2025, ~30 percent
- **Iconovo Pharma** – scaling up and readiness for first licenced product launches in 2024, ~20 percent
- **ICOone** – leveraging the opportunity to become the global leader within nasal inhalation, ~20 percent

The Bookbuilding will commence immediately following this announcement. Pricing and allocation of the new shares are expected to take place before the commencement of trading on Nasdaq First North Growth Market Stockholm at 09:00 CET on 9 February 2023. The Board of Directors may decide to extend or shorten the application period and can at any moment decide to terminate the Bookbuilding and thus refrain from carrying out the New Share Issue. Iconovo will announce the outcome of the New Share Issue in a subsequent press release after completion of the Bookbuilding.

The New Share Issue is, among other things, subject to resolution by the Board of Directors of Iconovo, pursuant to the authorisation given by the Annual General Meeting on 17 May 2022, to issue new shares following close of the Bookbuilding.

Several current shareholders, among others Eiffel, have expressed strong support for the New Share Issue and intend to participate in the New Share Issue with significant amounts. Eiffel's investment in the New Share Issue is intended to be made through a fund that is not previously a shareholder in Iconovo. In connection with the New Share Issue, Eiffel's intention is also that two funds that are currently shareholders in Iconovo will divest a total of 200,000 shares in Iconovo at a price per share corresponding to the subscription price in the New Share Issue. The Company's Chairman, Gunnar Gårdemyr, the Company's largest shareholder, Mats Johansson, and the Company's CEO Johan Wåborg have indicated interest in acquiring existing shares from Eiffel in that transaction. Eiffel's intention is to have increased its overall ownership in the Company after the New Share Issue and the planned sale of shares.

The Board of Directors of the Company deems, after an overall assessment and careful consideration, that a new share issue with deviation from the shareholders' preferential rights is a better alternative for the Company and the Company's shareholders than a rights issue and that objectively it is in the best interest of both the Company and its shareholders to carry out the New Share Issue. The Board of Directors' assessment is based on the fact that a directed new share issue enables the Company to raise capital quickly and cost efficiently. Raising capital quickly provides flexibility for potential investment possibilities in the short term, contributes to reduced exposure to price fluctuations on the capital market as well as provides the opportunity to benefit from the current interest in the Company's share among institutional investors. The cost of carrying out a directed new share issue is deemed to be lower than in a rights issue where, among other things, significant underwriting commitments from an underwriting syndicate would possibly have to be procured. In addition, the Board of Directors has a positive view on an increased shareholding in the Company among institutional investors. The Board of Director's overall assessment is thus that the reasons for carrying out the New Share Issue outweigh the reasons that justify the main rule that new issues shall be carried out with preferential rights for the shareholders. To ensure that the subscription price is established on market terms, the Board of Directors has resolved to carry out the Bookbuilding and it is therefore the Board of Directors' assessment that the subscription price will reflect prevailing demand and market conditions.

Lock-up

In connection with the New Share Issue, the Company has, subject to customary exceptions, agreed not to issue further shares for a period of 180 calendar days from the settlement date of the New Share Issue. In addition, the Company's Board of Directors that own shares, as well as the Company's CEO and CFO, have, subject to customary exceptions, agreed not to sell any shares in the Company during the same period.

Bringing forward the publication of the year-end report for the financial year 2022

Due to the New Share Issue, the Board of Directors of Iconovo has resolved that the Company's year-end report for the financial year 2022 will be published immediately after this press release instead of 17 February 2023, as previously communicated.

Advisers

In connection with the New Share Issue, the Company has retained Danske Bank as Sole Global Coordinator and Bookrunner and Setterwalls Advokatbyrå AB as legal adviser. Advokatfirman Schjødt is legal advisor to Danske Bank.

For further information, please contact:

Johan Wäborg, CEO

Tel: +46 707 78 51 71

E-mail: johan.waborg@iconovo.se

Important information

Publication, distribution or release of this press release may, in certain jurisdictions, be subject to restrictions by law and the persons in such jurisdictions where this press release has been published or distributed should inform themselves of and follow such legal restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with applicable rules in each jurisdiction. This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the Company in any jurisdiction where such an offer or solicitation would be illegal. In each Member State of the European Economic Area (“EEA”), this press release is directed only to “qualified investors” in the Member State in accordance with the Regulation (EU) 2017/1129 of the European Parliament and of the Council (the “Prospectus Regulation”) definition.

This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Africa, Switzerland, the United States, or in any other jurisdiction where such announcement, publication or distribution of the information would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations.

This press release may in the United Kingdom, be distributed and directed only to “qualified investors” as defined as (i) professional investors as set out in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”); or (ii) fall within Article 49(2)(a) to (d) (“entities with high net worth” etc.) of the Order, (all such persons together being referred to as “Relevant Persons”). An investment or investment activity to which this communication relates in the United Kingdom is available only to Relevant Persons and will only be carried out with Relevant Persons. Persons that are not Relevant Persons should not take any action based on this press release and should not act or rely on it.

This press release is not a prospectus for the purposes of the Prospectus Regulation and has not been approved by any regulatory authority in any jurisdiction. The Company has not authorised any offer to the public of shares or rights in any member state of the EEA and no prospectus has been or will be prepared in connection with the Issue. This press release neither identifies nor claims to identify risks (direct or indirect) which could be associated with an investment in new shares. An investment decision to acquire or subscribe for new shares in the Issue may only be made based on publicly available information, which has not been verified by Danske Bank. Danske Bank acts on behalf of the Company in connection with the Issue and not for the benefit of any other person or entity. Danske Bank is not responsible in relation to any other person or entity to provide the

protection which has been provided to their customer nor to give advice in connection with the Issue or any other topic mentioned herein.

Information to distributors

Solely for the purposes of the product governance requirements contained within: (a) EU Directive 2014/65/EU on markets in financial instruments, as amended (“MiFID II”); (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c) local implementing measures (together, the “MiFID II Product Governance Requirements”), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any “manufacturer” (for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the issued shares have been subject to a product approval process, which has determined that the shares are: (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in MiFID II; and (ii) eligible for distribution through all distribution channels as are permitted by MiFID II (the “Target Market Assessment”). Notwithstanding the Target Market Assessment, distributors should note that: the price of the shares may decline and investors could lose all or part of their investment; the shares offer no guaranteed income and no capital protection; and an investment in the shares is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the issue.

For the avoidance of doubt, the Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of MiFID II; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the shares.

Each distributor is responsible for undertaking its own target market assessment in respect of the shares and determining appropriate distribution channels.

Contacts

Johan Wäborg, CEO

+46 707 78 51 71

johan.waborg@iconovo.se

About Iconovo

Iconovo (Nasdaq First North Growth Market: ICO) develops new inhaled medicinal products in collaboration with international pharmaceutical companies. The company provides several types of patent-protected inhalers that can generate significant commercial opportunities in the development of novel pharmaceuticals and vaccines and at patent expirations for established pharmaceuticals. The most advanced project is a generic version of the asthma and COPD product Symbicort® which is expected to reach the market in 2024. Iconovo plans to market this product in the Nordic region through its subsidiary Iconovo Pharma, while the company's partner Amneal Pharmaceuticals has the rights in other parts of Europe and the United States. Certified Adviser is Erik Penser Bank AB.

This information is information that Iconovo is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-02-08 17:31 CET.

Attachments

[Iconovo AB evaluates the conditions to carry out a directed new share issue of approximately SEK 50 million and brings forward publication of the year-end report for the financial year 2022](#)